Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

New Releases: Dec 8, 2010


Septin9 Colorectal Cancer Test

USC, which was an early-access customer for SmartChip prior to its full commercial launch in August, will use the system to discover and validate biomarkers for pancreatic and colorectal cancer.

The firm expects the study to include around 300 primary care physicians and up to 3,000 patients getting the Epi proColon test in Germany and Switzerland.

The funding will go toward ongoing commercialization efforts for VeriStrat, the company's protein biomarker-based companion diagnostic for non-small cell lung cancer.

ArcticDx's macular degeneration prognostic test officially launched as an LDT in the US in September, and the firm is targeting FDA approval to help propel it globally.

Genomic Health discussed the status of its ongoing work with Pfizer in renal cancer and suggested it might eventually develop a companion test for Erbitux that gauges mutations "beyond KRAS."

Under the terms of the agreement, DPC Lebanon will distribute Epigenomics' test in Lebanon, the United Arab Emirates, Saudi Arabia, Qatar, Kuwait, Syria, Jordan, and Egypt.

A number of prominent proteomics-based diagnostics developers were recipients of the grant and tax credit awards, which are being provided by the IRS through the Patient Protection and Affordable Care Act's Qualifying Therapeutic Discovery Project Program.

The company also said that it will be launching the test in China in the fourth quarter of 2010 and in the US in the first half of 2011.

In results reported Thursday, the company said that its Cologuard test achieved of 64 percent sensitivity for pre-cancers and 85 percent for cancer and a specificity of 88 percent.


Nature News reports on how meeting cancellations and related costs are affecting scientific societies.

In a new ruling, Canada's Supreme Court upheld the country's genetic non-discrimination law, the Canadian Press reports.

COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.

In PLOS this week: analysis of insertions throughout Shigella genomes, antigen production in malaria parasites, and more.